Galectin Therapeutics
GALT
GALT
61 hedge funds and large institutions have $20M invested in Galectin Therapeutics in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
38% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $2.12M
45% less capital invested
Capital invested by funds: $36.2M → $20M (-$16.2M)
Holders
61
Holding in Top 10
–
Calls
$1.3M
Puts
$2.12M
Top Buyers
| 1 | +$578K | |
| 2 | +$498K | |
| 3 | +$324K | |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$262K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$223K |
Top Sellers
| 1 | -$1.56M | |
| 2 | -$991K | |
| 3 | -$786K | |
| 4 |
Millennium Management
New York
|
-$676K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$187K |